Winton Group’s Cardiff Oncology CRDF Stock Holding History

Winton Group’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-43,865	Closed	-$292K	–	1089
2021 Q3	$292K	Buy	43,865 +20,381	+87%	+$128K	0.02%	1107
2021 Q2	$156K	Buy	+23,484	New	+$199K	0.01%	1367

Other funds holding CRDF

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Winton Group's CRDF Position: Q4 2021 in Review

Winton Group sold out of Cardiff Oncology (CRDF) in Q4 2021, closing a stake of 43,865 shares — an estimated $292K sold.

Winton Group first reported a position in CRDF in Q2 2021 and held it in 2 quarters. The position peaked at $292K in Q3 2021. 87 funds tracked by Wall St. Rank hold CRDF as of Q4 2021.

Winton Group reported no remaining Cardiff Oncology position as of Q4 2021 after selling out during the quarter.
Winton Group sold 43,865 Cardiff Oncology shares in Q4 2021, an estimated $292K.
Winton Group first reported a position in Cardiff Oncology in Q2 2021 and held it in 2 quarters.
Winton Group's Cardiff Oncology position peaked at $292K in Q3 2021.
87 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2021.

Based on Winton Group's 13F filing for Q4 2021, filed 10 Feb 2022.